Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5744667

COc1cc2c(CC(N)=O)cnc(C(=O)c3cccc(OC(C)C)c3)c2cc1OC.O=C(O)C(F)(F)F

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFPT1 Q06210 1/20 0.68
DPP4 P27487 2/20 0.40
PTGDR2 Q9Y5Y4 4/20 0.38
APAF1 O14727 1/20 0.37
NSD2 O96028 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FOS P01100 1/20 0.37
JUN P05412 1/20 0.37
F3 P13726 2/20 0.36
F10 P00742 1/20 0.36
F7 P08709 1/20 0.36
LNPEP Q9UIQ6 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367662 0.94 GFPT1 (0.66) GFPT1DPP4PTGDR2APAF1NSD2
Trifluoroacetic Acid SCHEMBL6108469 0.93 GFPT1 (0.70) GFPT1DPP4PTGDR2FOSJUN
Trifluoroacetic Acid SCHEMBL5765564 0.93 GFPT1 (0.57) GFPT1DPP4PTGDR2APAF1NSD2
Trifluoroacetic Acid SCHEMBL5745098 0.91 GFPT1 (0.66) GFPT1DPP4APAF1NSD2CASP3
Trifluoroacetic Acid SCHEMBL5768365 0.91 GFPT1 (0.70) GFPT1DPP4PTGDR2APAF1NSD2
SCHEMBL1366610 0.88 GFPT1 (0.67) GFPT1PTGDR2
SCHEMBL1369897 0.87 GFPT1 (0.55) GFPT1DPP4PTGDR2APAF1NSD2
Trifluoroacetic Acid SCHEMBL6108761 0.86 GFPT1 (0.61) GFPT1APAF1NSD2CASP3SENP8
Trifluoroacetic Acid SCHEMBL6108973 0.86 GFPT1 (0.73) GFPT1DPP4F3PDE10AMET
SCHEMBL6108471 0.86 GFPT1 (0.68) GFPT1DPP4PTGDR2APAF1NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS GFPT1 1/4885DPP4 134/4885PTGDR2 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.